ASLAN Selects PharmaNet/i3 as Strategic Partner for Oncology Development
News Mar 07, 2012
PharmaNet/i3 has announced that ASLAN Pharmaceuticals has selected PharmaNet/i3 as a Strategic Partner supporting the development of their oncology portfolio in Asia, and conducting Phase I and Phase II clinical trials for two of ASLAN’s compounds.
Dr. Alan Barge, ASLAN’s Chief Medical Officer, stated, “We chose to work with PharmaNet/i3 because of the commitment and passion shown by their team and the creative thinking they brought to our oncology development strategy. ASLAN is keen to build a strong strategic relationship with PharmaNet/i3, a company that shares our focus on quality and efficiency.”
PharmaNet/i3 has been conducting clinical studies for innovative oncology products since 1996 and has an experienced team, including on-staff oncologists, dedicated to the development of cancer treatments.
The Company has extensive experience in the development of a variety of cytotoxic chemotherapies, monoclonal antibodies, pathway inhibitors and therapeutic vaccines.
More than four hundred local, regional and global oncology clinical trials have been awarded to PharmaNet/i3 in the past five years, including more than a dozen registration programs, seven of which resulted in NDA/MAA approvals.
“Clinical development of oncology therapeutics requires a special understanding of the mechanism of action and the different approaches to cancer therapies,” commented Dalvir Gill, PhD, President, Phase II – IV Development, PharmaNet/i3.
Gill continued, “ASLAN has a novel and creative approach to personalized medicine and combination therapy. We will work closely with ASLAN to address the unique methodologies needed to evaluate the efficacy and safety of their innovative products and look forward to a long and productive relationship.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE